Clinical significance of increased peripheral venous blood adipocyte-specific protein FABP4 after joint replacement

Zhuo Wang, MDa,∗, Na Buqi, MDa, Pingji Zhang, BSa, Yanxun Wang, MDa, Yanwei Lv, MSb, Guisheng An, BSb

Abstract
A new method of diagnosing fat embolism (FE) at the molecular level was proposed, and the diagnostic value of adipocyte-specific protein fatty acid-binding protein 4 (Homo sapiens [human]) gene ID = 2167 (FABP4) for FE was preliminarily explored. Eight joint replacement patients, 5 internal medicine patients, and 6 healthy persons were recruited. Serum of internal medicine patients, healthy people, and patients before and 24 hours after joint replacement were taken as study samples. Subcutaneous adipose, intra-articular adipose and intramedullary yellow bone marrow of patients undergoing joint replacement were taken as study samples. The level of FABP4 in the above samples was detected by enzyme-linked immunoassay. Normal distribution was tested. Paired sample T test was used for self-control. Univariate analysis of variance was used for multigroup comparison. There was no significant difference in serum FABP4 level between healthy persons, medical patients, and preoperative patients. The FABP4 level in yellow bone marrow and subcutaneous adipose was significantly higher than that in serum of healthy people, medical patients, and preoperative patients. FABP4 level in the serum after joint replacement was significantly higher than that before joint replacement. FABP4 may be a specific indicator of FE diagnosis, but further studies are needed to confirm its clinical value.

Keywords: adipocyte, diagnosis, embolism, fat, protein

1. Introduction
Fat embolism (FE) is a syndrome caused by fat globules entering the circulatory system, with or without clinical manifestations.[1] Fat embolism syndrome (FES) is a clinical syndrome in which fat globules enter the bloodstream and cause a range of clinical symptoms and signs. Thus, FES is a serious consequence of FE.[2] Due to the lack of sensitive diagnostic indicators of FE, the incidence of FE is underestimated. FE and FES often occur after trauma, fracture, orthopedic surgery, liposuction, and fat autotransplantation. The incidence of FE in patients with trauma and long bone fractures was reported as high as 90%,[3–5] and 22.5% to 29% of them developed FES.[6,7] It was reported that the mortality rate of FE varied greatly. Some authors reported mortality rates up to 60%.[8] At present, clinical diagnosis of FE mainly depends on pathologic diagnosis. There is no gold standard for diagnosis of FES.[2] The widely used diagnostic criteria of FES were derived from the framework proposed by Gurd and Wilson in 1974.[9] Though some authors added some new diagnostic indicators, such as fat droplets found in urine, sputum, or alveolar lavage fluid.[10–12] But no diagnostic parameter of them was unique to FE. At present, laboratory tests of FE and FES show poor specificity and sensitivity leading to high rate of misdiagnosis.[13] It is difficult to distinguish FE or FES from traumatic brain injury, lung injury, and other diseases. Over the past 40 years, the diagnostic criteria of FE and FES have rarely changed, resulting in a large number of patients being misdiagnosed and missed. Therefore, it is an urgent need to search for FE and FES diagnostic indicators with high sensitivity and specificity.

There are 2 main sources of embolus for FE: bone marrow source, and the source of adipocyte around the subcutaneous or visceral organs.

Adipocytes contain triglycerides. Triglycerides and chyle particles are also present in normal blood circulation, but there is no adipocyte-specific component. If the adipocyte-specific component is found in circulating blood, it indicates that the adipocyte component enters the blood circulation, which can prove the occurrence of FE. Therefore, the idea of diagnosing FE at the molecular level was proposed. To confirm the above hypothesis, we selected human adipocyte-specific protein FABP4...
The yellow marrow samples (1 cm³) and adipose samples (1 cm³) were taken from patients with hip arthroplasty or knee arthroplasty, and were preserved at −80°C refrigerator.

2.2. Processing of adipose and yellow bone marrow

One hundred milligrams of specimens were weighed. Cut them into small pieces and washed twice with 1 mL phosphate-buffered saline. After centrifuging for 5 minutes at 500g, the supernatant was discarded carefully. One milliliter total protein extraction buffer (Beijing Solarbio Biological Technology Company Ltd, Beijing, China) was added to tissue samples, after mixed by oscillation, and the tissue suspension was transferred to the precooled glass to homogenate for 6 to 10 times. The tissue suspension of homogenate was transferred to a new 1.5-mL centrifuge tube, incubated on ice for 30 minutes, and mixed with oscillations every 10 minutes centrifuged for 10 minutes (4°C, 1400g). Then supernatant was collected for subsequent experiments or preserved at −80°C.

Melted and remained at 2°C to 8°C temperature, a certain amount of phosphate-buffered saline (pH 7.4) was added to the specimen after homogenization thoroughly, it was centrifuged at 1300g for 20 minutes. The supernatant was collected and subpacked.

2.3. FABP4 detection

Human FABP4 enzyme-linked immunoassay kit produced by ABCAM was used. Detection sensitivity 2.7 pg/mL. Test type: sandwich (quantitative).

2.4. Statistical methods

Data are presented as mean ± standard error mean. All statistical analyses were performed using SPSS 11.0. Normal distribution of samples was tested, where appropriate, to select parametric or nonparametric tests as indicated in the figure legends. The paired t test or 1-way analysis of variance for multiple comparisons was used to determine P-values, unless indicated differently in the figure legend.

3. Results

Nineteen subjects were recruited, including 6 healthy subjects, 5 internal medicine patients, and 8 operation patients (2 patients only provided discarded adipose tissue in joint cavity). General information is shown in Table 1.

The major diagnoses of the patients in the medical group were: 2 patients of community-acquired pneumonia, 1 patient of bronchiectasis combined with infection, 1 patient of acute...
exacerbation of chronic obstructive pulmonary disease, and 1 patient of bronchial asthma combined with pulmonary infection. The main diagnoses of the patients in the operation group on admission were: 2 patients of old femoral neck fracture and 6 patients of knee osteoarthritis. Total-hip arthroplasties were performed in 2 patients and total-knee arthroplasties in 6 patients. No skin petechiae and ecchymosis were found except near the wound. All the 8 patients presented increased blood leukocyte, increased neutrophils, decreased hemoglobin, decreased platelet, and postoperative low fever for 2 to 3 days. All the 7 patients had no other complaints of discomfort except the pain at the surgical site. One patient (male, 65 years old, right hip replacement) presented dyspnea on the day after the operation, with respiratory rates of 25 to 35 bpm, heart rates of 100 to 120 bpm, clear consciousness, breathing sounds in both the lungs, no dry and wet rales, and no heart murmur. Blood gas analysis: FiO₂ 100%, pH 4.405, CO₂ 28.5 mm Hg, PO₂ 188.6 mm Hg, lactic acid 3.9 mmol/L. N-Terminal pro-brain natriuretic peptide (Nt-proBNP) 1854 pg/mL. Bedside chest X-ray showed increased bronchovascular shadows (Fig. 1), and lung computer tomography (CT) showed ground-glass shadows of both lower lungs (Fig. 2). Preoperative peripheral venous blood FABP4 concentration was 314.04 pg/mL, and postoperative 489.13 pg/mL. FES and cardiac insufficiency were suspected. Dexamethasone 10 mg, intravenous input, once a day was given for 3 days. Albumin 20 g, intravenous drip, once a day for 3 days, furosemide 20 mg, albumin intravenous input, once a day, after albumin for 3 days. The symptoms gradually improved and the patient was discharged. No abnormality was found at follow-up outside the hospital.

There were 23 serum samples: healthy control serum, serum of internal medicine patients, serum of preoperative patients, serum of postoperative patients. There were 20 adipose tissue specimens: subcutaneous adipose, intra-articular adipose, and yellow bone marrow. FABP4 concentration of each group is shown in Table 2. There was no significant difference in serum FABP4 levels between healthy controls, internal medicine patients, and preoperative patients. FABP4 levels of subcutaneous adipose and yellow bone marrow were significantly higher than serum FABP4 levels of healthy controls, internal medicine patients and preoperative patients. FABP4 levels of intra-articular adipose tissue were significantly lower than serum FABP4 levels of healthy controls, internal medicine patients, preoperative patients and postoperative patients, as well as subcutaneous adipose and yellow bone marrow FABP4 levels.

4. Discussion

The diagnosis of FES mainly relies on pathologic examination of the lung, brain, kidney, and other parts to discover the presence of fat emboli in small blood vessels. However, this method is mostly used for postmortem autopsy of patients, which greatly limits its application. Unlike thromboemboli, fat emboli are small and dispersed, mostly in the blood circulation in the form of fat droplets or incarcerated in small blood vessels. Therefore, radiologic examination, neither CT nor magnetic resonance imaging are able to demonstrate specific manifestations.[14] Fat droplets were also found in blood, sputum, alveolar lavage fluid, and urine of healthy people.[8,15] Because under normal circumstances, the human blood circulation also contains triglycerides, cholesterol and chylous particles, and other components. At present, there is no simple and convenient method with high specificity and sensitivity to diagnose FE.

Diagnostic standard of FES proposed by Gurd and Wilson in 1974 is generally adopted in clinic. A positive diagnosis was made on finding of least 1 major feature and 4 minor features.[9] Main criteria: respiratory insufficiency; cerebral involvement; petechial rash; minor criteria: pyrexia; tachycardia; retinal changes; jaundice; and renal changes. Laboratory features: anemia; thrombocytopenia; high erythrocyte sedimentation rate; and fat macroglobuloneida.[9] As the standard is mainly based on clinical manifestations, all the indicators examined in laboratory lack specificity and the rate of missed diagnosis is high. Also, many patients are misdiagnosed as traumatic brain injury, lung injury, and other diseases. Some authors had tried to improve the diagnosis of FES,[16–18] and others used a scoring system to evaluate high-risk patients to assist the diagnosis of FES, but the
lack of specificity and effectiveness has limited the clinical application.\textsuperscript{[19]}

There are 2 main sources of embolus for FE:

1. Bone marrow source: After 18 years of age, the body’s long bones are almost full of yellow bone marrow. The yellow bone marrow is mainly composed of adipose tissue. When a long bone fracture occurs, the adipocytes in the bone marrow cavity are squeezed and damaged and enter the blood circulation through the damaged blood vessels and FE happens. During hip and knee replacement, one end of the prosthesis should be pushed into damaged vessels. FE occurred. The local pressure or tension was so high that adipocytes were pushed into damaged vessels and FE happens. During liposuction, small vessels were damaged and adipocytes were pushed into the blood circulation, causing FE. Fat droplets were found in the peripheral blood of 100% of animals during liposuction.\textsuperscript{[20]} During liposuction, small vessels were damaged. Adipocytes and lipid were pushed into the blood circulation.\textsuperscript{[21–23]} Fat particles were visible in all peripheral blood samples taken at the middle and end process of liposuction. These blood samples showed different patterns of fat particles. The number of fat particles in blood samples at the end of liposuction was significantly higher than that at the middle process of liposuction.\textsuperscript{[20]} When fat transplantation was performed, adipocytes were injected into the target site. The local pressure or tension was so high that adipocytes were pushed into damaged vessels. FE occurred. The adipocytes around the subcutaneous or visceral organs are other major sources of the FE embolus. Patients with trauma and fat transplantation were at high risk for FE.\textsuperscript{[3,8]}

2. The source of adipocyte around the subcutaneous or visceral organs: When trauma occurs, the soft tissue is squeezed and damaged, and adipocytes are pushed through the damaged vessels and into blood circulation, causing FE. Fat droplets were found in the peripheral blood of 100% of animals during liposuction.\textsuperscript{[20]} During liposuction, small vessels were damaged. Adipocytes and lipid were pushed into the blood circulation.\textsuperscript{[21–23]} Fat particles were visible in all peripheral blood samples taken at the middle and end process of liposuction. These blood samples showed different patterns of fat particles. The number of fat particles in blood samples at the end of liposuction was significantly higher than that at the middle process of liposuction.\textsuperscript{[20]} When fat transplantation was performed, adipocytes were injected into the target site. The local pressure or tension was so high that adipocytes were pushed into damaged vessels. FE occurred. The adipocytes around the subcutaneous or visceral organs are other major sources of the FE embolus. Patients with trauma and fat transplantation were at high risk for FE.\textsuperscript{[3,8]}

Normally, triglycerides and chylous granules are present in the blood circulation, but there is no adipocyte-specific component in the blood circulation. If adipocyte-specific components are found in the blood circulation, indicating that adipocyte components outside the circulation enter the blood circulation. And the occurrence of FE can be proved. If the adipocyte-specific component (biomarker) can be found, the occurrence of FE can be confirmed as long as such biomarkers are detected in peripheral blood. Therefore, the author proposes this idea of diagnosing FE at the molecular level. To verify the above hypothesis, the author chose protein FABP4 as the marker. FABP4 is found in the cytoplasm and nucleus of adipocytes, and it is a specific marker of adipocytes, participating in lipid metabolism. Although FABP4 can be detected in peripheral blood of normal people, FABP4 can still be used as candidate diagnostic indicators of FE because the content of FABP4 in adipocytes is much higher than that in other tissues. When FE occurs, smaller fragments can travel through the pulmonary circulation to the systemic circulation,\textsuperscript{[14,15]} so adipocyte-specific proteins can be detected in the peripheral blood. Therefore, the author proposed the hypothesis: if the adipocyte-specific protein FABP4 was detected in the peripheral blood of the high-risk group with FE, and the content of this protein was significantly higher than that in other tissues. When FE occurs, smaller fragments can travel through the pulmonary circulation to the systemic circulation,\textsuperscript{[14,15]} so adipocyte-specific proteins can be detected in the peripheral blood. Therefore, the author proposed the hypothesis: if the adipocyte-specific protein FABP4 was detected in the peripheral blood of the high-risk group with FE, and the content of this protein was significantly higher than that in the peripheral blood of normal people, it shows the occurrence of FE. When the concentration of FABP4 reaches a certain level, there will be clinical symptoms, namely FES. If this hypothesis can be verified, only a small amount of peripheral blood of patients can be used for diagnosis. The results can be used to distinguish FES from brain injury and lung injury.

To test this hypothesis, we conducted a preliminary exploration in a small number of subjects. The results of this study showed that: the content of FABP4 in subcutaneous adipose and yellow bone marrow was very high, and significantly higher than the content of FABP4 in serum of the normal control group, internal medicine patients, and preoperative patients; there was no significant difference in FABP4 content in serum of normal control group, internal medicine patients, and preoperative patients; and the serum FABP4 content of postoperative patients

### Table 2

**FABP4 concentrations in each group.**

| Items                | Groups                              | Serum of healthy control subjects | Serum of internal medicine patients | Serum of preoperative patients | Serum of postoperative patients | Subcutaneous adipose | Intra-articular adipose | Yellow bone marrow |
|----------------------|-------------------------------------|----------------------------------|-----------------------------------|--------------------------------|--------------------------------|----------------------|-----------------------|---------------------|
| Number               |                                     | 6                                | 5                                 | 6                              | 6                              | 8                    | 8                     | 6                   |
| FABP4 (maximum)      |                                     | 415.17                           | 446.87                            | 435.55                         | 489.13                         | 565.23               | 164.35                | 547.25              |
| FABP4 (minimum)      |                                     | 307.25                           | 281.58                            | 314.04                         | 395.55                         | 512.93               | 9.32                  | 402.72              |
| FABP4 (mean ± standard deviation, pg/mL) |                      | 363.47 ± 41.65                   | 357.51 ± 74.39                    | 381.96 ± 44.49                 | 442.21 ± 36.49Δ                | 538.83 ± 17.17†,‡,|| | 77.93 ± 63.52*†,| 507.96 ± 54.02*†,‡,|| |

\*Because the serum was from the same patient before and after surgery, the 2 groups were compared by paired t test. The data in this table are analyzed by multigroup 1-way analysis of variance (ANOVA) for serum of preoperative patients and other 5 groups, and by multigroup 1-way ANOVA for serum of postoperative patients and other 5 groups, which are combined in this table to save space.

FABP4 = fatty acid-binding protein 4 (Homo sapiens [human]) gene ID = 2167.

1. There was a significant difference compared with healthy people serum, \( P < .05 \).
2. There was a significant difference compared with serum of preoperative patients, \( P < .05 \).
3. There were significant differences compared with serum of internal medicine patients, \( P < .05 \).
4. There was significant difference compared with extra-arterial adipose, \( P < .05 \).
5. There was a significant difference compared with serum of postoperative patients, \( P < .05 \).
6. There was a significant difference between preoperative and postoperative patients, \( P = .05 \).
was significantly higher than that of preoperative patients. The results are encouraging. It is proved that FABP4 could be used as FE-specific diagnostic indicators. A total of 8 joint replacement patients were recruited in this study, 7 of whom had no obvious complaints of discomfort except wound pain postoperation. All the 8 patients showed increased leukocyte, decreased platelet counts, and decreased hemoglobin levels in routine blood test 24 hours after operation. The body temperature was 1 to 3 days low-grade fever after the operation, and 7 patients were discharged 3 to 4 days after the operation. After discharge, no obvious abnormality was found. One patient developed dyspnea postoperatively and was diagnosed with FES. Although this patient met the diagnostic criteria of FES proposed by Gurd and Wilson in 1974, because the clinical symptoms and auxiliary examination of this patient were difficult to exclude the common peripertroperative complications of cardiac dysfunction, the doctor made the diagnosis of FES and cardiac dysfunction, then took targeted treatment. Anticoagulation therapy was not given because the thromboembolism was not found and the risk of bleeding was high. The patient’s symptoms improved significantly after treatment. FABP4 was detected in the later, and the results showed that the content of FABP4 in the blood postoperation was significantly higher than that before operation, further confirming the diagnosis of FES. Less than 2% of FES patients have typical dyspnea, delirium, and skin petechiae.[24] A large number of FE patients are missed. Therefore, it is speculated that other patients are likely to have asymptomatic FE. The study also found that the FABP4 content in the adipose tissue in the articular cavity was very low, which was significantly lower than that in other groups. Some studies have shown that the source of bone marrow adipose tissue is different from the source of bone marrow adipose tissue and subcutaneous adipose tissue is different from the source of bone marrow adipose tissue and subcutaneous adipose tissue is still unclear, and further research is needed.

The advantage of this study is that it provides a new way to diagnose FE at molecular level, and provides a possibility to search for sensitive and specific diagnostic indicators of FE. The disadvantage is that due to the lack of previous relevant studies, this study is an initial exploratory study with few patients.

5. Conclusion

1. This study provides preliminary research data for the diagnosis of FE at molecular level, and provides a possibility to search for sensitive and specific diagnostic indicators of FE. The disadvantage is that due to the lack of previous relevant studies, this study is an initial exploratory study with few patients.

Acknowledgment

The authors thank Dr. Chu Yaming, Dr. Jiang Xu, Dr. Lv Ming, Dr. Tang Jing, Dr. Qiu Shuang, Dr. Yang Jie, Dr. Wang Xiaofei, Dr. Chen Tianyi, Dr. Dai Li, Dr. Wang Yan, and nurse Xu Zhixin in Beijing Jishuitan Hospital.

Author contributions

Dr. Zhao Wang designed and organized the study. Other authors participated in and conducted the study.

References

[1] Von Bergmann E. Ein Fall tödlicher Fettembolie. Berl Klin Wochenschr 1873;10:385.
[2] Fukumoto LE, Fukumoto KD. Fat embolism syndrome. Nurs Clin North Am 2018;53:335–47.
[3] Eriksson EA, Pellegrini DC, Vanderkolk WE, et al. Incidence of pulmonary fat embolism at autopsy: an undiagnosed epidemic. J Trauma 2011;71:312–5.
[4] Bulger EM, Smith DG, Maier RV, et al. Fat embolism syndrome. A 10-year review. Arch Surg 1997;132:433–9. PMID:9108767 DOI: 10.1001/archsurg.1997.01430280109019.
[5] Talbott M, Schemitsch EH. Fat embolism syndrome: history, definition and epidemiology. Injury 2006;37:53–7.
[6] Chowdhary V, Mehta V, Bajaj T, et al. Rare imaging of a known entity: fat embolism seen on CT in lower extremity vein after trauma. Radiol Case Rep 2017;12:488–90.
[7] Shakh N. Emergency management of fat embolism syndrome. J Emerg Trauma Shock 2009;2:29–33.
[8] Mendoza-Morales RC, Camberos-Nava EY, Luna-Rosas A, et al. A fatal case of systemic fat embolism resulting from gluteal injections of vitamin e for cosmetic enhancement. Forensic Sci Int 2016;259:e1–4.
[9] Gurd AR, Wilson RI. The fat embolism. J Bone Joint Surg 1974;56:408–16.
[10] Akhtar S. Fat embolism. Anesthesiol Clin 2009;27:533–50.
[11] Chan KM, Tham KT, Chiu HS, et al. Post-traumatic fat embolism—its clinical and subclinical presentations. J Trauma 1984;24:45–9.
[12] Pelchen LF. Fat embolism. An appraisal of the problem. Clin Orthop Relat Res 1984;187:3–17.
[13] Georgopoulos D, Bouras D. Fat embolism syndrome clinical examination is still the preferable diagnostic method. Chest 2003;123:982–3.
[14] Godoy DA, Di Napoli M, Rabinstein AA. Cerebral fat embolism: recognition, complications, and prognosis. Neurocrit Care 2018; 29:358–65.
[15] Pelchen LF, Fat embolism. An appraisal of the problem. Clin Orthop Relat Res 1984;187:3–17.
[16] Lee SC, Yoon JY, Nam CH, et al. Cerebral fat embolism syndrome after simultaneous bilateral total knee arthroplasty. J Arthroplast 2012; 27:409–14.
[17] Baguley IJ, Heriseanu RE, Cameron ID, et al. A critical review of the pathophysiology of dysautonomia following traumatic brain injury. Neurocrit Care 2008;8:293–300.
[18] Rahbstein AA, Benzroth EE. Treatment of paroxysmal sympathetic hyperactivity. Curr Treat Options Neurol 2008;10:151–7.
[19] Schonfeld SA, Ploysongsang Y, Di Lisio R, et al. Fat embolism prophylaxis with corticosteroid. A prospective study in high-risk patients. Ann Int Med 1983;99:438–41.
[20] Senen D, Atakol D, Ertan G, et al. Evaluation of the risk of systemic fat mobilization and fat embolus following liposuction with dry and tumescent technique: an experimental study on rats. Aesthetic Plast Surg 2009;33:730–7.
[21] Filomeno LT, Carelli CR, Figueiredo da Silva NC, et al. Embolia gordurosa: uma revisão para a prática ortopédica atual. Acta Ortop Bras 2005;13:196–208.
[22] Rügmann C, Ruschel N, Streiff R, et al. Embolie grasséuse pulmonaire après liposuccion. Ann Franq dAnesth Réanim 2006;25:189–92.
[23] El-Al KKM, Gourlay T. Assessment of the risk of systemic fat mobilization and fat embolism as a consequence of liposuction: ex vivo study. Plast Reconstr Surg 2006;117:2269–76.
[24] de Lima E, Souza R, Appaua BT, et al. Severe fat embolism in perioperative abdominal liposuction and fat grafting. Braz J Anesthesiol 2016;66:324–8.